BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

In Segment A, participants will get unique doses and schedules of oral ABBV-744 tablet to identify safe dosing routine. Added individuals will probably be enrolled at the discovered monotherapy dosign regimen. In Section B, participants will get oral ruxolitinib and ABBV-744 is going to be provided as "add-on" therapy. In Section C, participants wi